Cytokinetics, Incorporated Announces Its Initial Public Offering
SOUTH SAN FRANCISCO, Calif. - April 29, 2004
Cytokinetics, Inc. (Nasdaq: CYTK) today announced the pricing of its initial public offering of 6,900,000 shares of its common stock at a price of $13.00 per share. All of the shares are being sold by Cytokinetics. In addition, the underwriters have a 30-day option to purchase up to an additional 1,035,000 shares from Cytokinetics at the initial public offering price less the underwriting discount. Cytokinetics' common stock will be listed on the Nasdaq National Market under the symbol "CYTK."
Goldman, Sachs & Co. is acting as book-runner and lead manager, and Credit Suisse First Boston, Pacific Growth Equities, LLC and Lazard are acting as co-managers.
A final prospectus for the offering may be obtained when available from Goldman, Sachs & Co.'s prospectus department at 85 Broad Street, New York, New York 10004, by telephone at 212-902-1171 or by faxing a request to 212-902-9316.
About Cytokinetics
Cytokinetics is a leading biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule drugs that specifically target the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Cytokinetics' focus on the cytoskeleton enables it to develop novel and potentially safer and more effective classes of drugs directed at treatments for cancer, cardiovascular disease, fungal diseases and other diseases. Cytokinetics has developed a cell biology driven approach and proprietary technologies to evaluate the function of many interacting proteins in the complex environment of the intact human cell. Cytokinetics employs the PUMA™ system and Cytometrix™ technologies to enable early identification and automated prioritization of compounds that are highly selective for their intended protein targets without other cellular effects, and are thereby less likely to give rise to clinical side effects. Cytokinetics and GlaxoSmithKline have entered into a strategic alliance to discover, develop and commercialize small molecule therapeutics targeting human mitotic kinesins for applications in the treatment of cancer and other diseases. GlaxoSmithKline is conducting Phase II clinical trials with SB-715992 and is expecting to initiate Phase I clinical trials in early 2004 for SB-743921, each a drug candidate that has emerged from the strategic alliance. Additional information about Cytokinetics can be obtained at www.cytokinetics.com.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on April 2, 2004. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 and it is the Company's intent that such statements be protected by the safe harbor created thereby. Examples of such statements include, but are not limited to, statements relating to the potential benefits of the Company's drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various factors. Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates that could slow or prevent product approval or market acceptance (including the risk that uncertainty of patent protection for the Company's intellectual property or trade secrets, the Company's ability to obtain additional financing if necessary and unanticipated research and development and other costs). For further information regarding these and other risks related to the Company's business, investors should consult the Company's filings with the Securities and Exchange Commission, including its registration statement on Form S-1 relating to the initial public offering of shares of its common stock and other periodic filing with the SEC. Cytokinetics does not undertake any obligation to update forward-looking statements.
